Gynaecological Cancers Clinical Trial
Official title:
ATARI: ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss
ATARI trial tests the ATR inhibitor drug AZD6738 and a PARP inhibitor drug olaparib in patients with relapsed gynecological cancers to assess the response in groups of patients selected based on their cancer cell subtype and the presence of an abnormality in ARID1A gene.
ATARI is a multi-centre, open-label, multiple two-stage parallel cohorts phase II clinical
trial for patients with relapsed gynaecological cancers, with ARID1A-deficient ('loss') and
"no loss."
The trial tests the ATR inhibitor drug AZD6738 and a PARP inhibitor drug olaparib to assess
the response in groups of patients selected based on their cancer cell subtype and the
presence of an abnormality in ARID1A.
The treatment groups are: 1A - Women with clear cell subtype with (ovarian/uterus) ARID1A
loss treated with AZD6738. 1B - Women with clear cell subtype with (ovarian/uterus) ARID1A
loss treated with AZD6738 + olaparib. 2 - Women with clear cell subtype (ovarian/uterus) with
no ARID1A loss treated with AZD6738 and olaparib. 3 - Women with other rare gynaecological
cancers (carcinosarcoma, cervical, endometrioid type) irrespective of ARID1A loss treated
with AZD6738 and olaparib.
;